Novocure aims to plough a new field
Lung cancer approval for the group’s electric fields-based therapy could come this year, but Novocure has broader solid tumour ambitions.
Medtech investments hold up despite market turmoil
Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.
A year to forget for medtech stocks
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
Medtech approvals stagnate
Device approvals hit a nine-year low in 2022, as the FDA takes its foot further off the gas.
An annus horribilis for medtech flotations
Bausch & Lomb saves 2022's medtech IPO scene from washout as markets close for new entrants.
Few big bangs in a quiet year for medtech mergers
J&J's $17bn swoop for Abiomed accounted for 42% of medtech M&A spend last year.
